<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24069487</PMID><DateCompleted><Year>2014</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1935-2735</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>9</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>PLoS neglected tropical diseases</Title><ISOAbbreviation>PLoS Negl Trop Dis</ISOAbbreviation></Journal><ArticleTitle>Lipidated dengue-2 envelope protein domain III independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement.</ArticleTitle><Pagination><StartPage>e2432</StartPage><MedlinePgn>e2432</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2432</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pntd.0002432</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Dengue virus is a mosquito-transmitted virus that can cause self-limiting dengue fever, severe life-threatening dengue hemorrhagic fever and dengue shock syndrome. The existence of four serotypes of dengue virus has complicated the development of an effective and safe dengue vaccine. Recently, a clinical phase 2b trial of Sanofi Pasteur's CYD tetravalent dengue vaccine revealed that the vaccine did not confer full protection against dengue-2 virus. New approaches to dengue vaccine development are urgently needed. Our approach represents a promising method of dengue vaccine development and may even complement the deficiencies of the CYD tetravalent dengue vaccine.</AbstractText><AbstractText Label="METHODOLOGY/PRINCIPAL FINDINGS" NlmCategory="RESULTS">Two important components of a vaccine, the immunogen and immunopotentiator, were combined into a single construct to generate a new generation of vaccines. We selected dengue-2 envelope protein domain III (D2ED III) as the immunogen and expressed this protein in lipidated form in Escherichia coli, yielding an immunogen with intrinsic immunopotentiation activity. The formulation containing lipidated D2ED III (LD2ED III) in the absence of exogenous adjuvant elicited higher D2ED III-specific antibody responses than those obtained from its nonlipidated counterpart, D2ED III, and dengue-2 virus. In addition, the avidity and neutralizing capacity of the antibodies induced by LD2ED III were higher than those elicited by D2ED III and dengue-2 virus. Importantly, we showed that after lipidation, the subunit candidate LD2ED III exhibited increased immunogenicity while reducing the potential risk of antibody-dependent enhancement of infection in mice.</AbstractText><AbstractText Label="CONCLUSIONS/SIGNIFICANCE" NlmCategory="CONCLUSIONS">Our study suggests that the lipidated subunit vaccine approach could be applied to other serotypes of dengue virus and other pathogens.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Chen-Yi</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Chien-Hsiung</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Chun-Hsiang</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Jy-Ping</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Mei-Yu</ForeName><Initials>MY</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hsueh-Hung</ForeName><Initials>HH</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shih-Jen</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Pele</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Leng</LastName><ForeName>Chih-Hsiang</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hsin-Wei</ForeName><Initials>HW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Negl Trop Dis</MedlineTA><NlmUniqueID>101291488</NlmUniqueID><ISSNLinking>1935-2727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053059">Dengue Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C051821">E-glycoprotein, Dengue virus type 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019067" MajorTopicYN="Y">Antibody-Dependent Enhancement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053059" MajorTopicYN="N">Dengue Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>I have read the journal's policy and have the following conflicts: HWC, CHL, SJL, and PC are named on patents relating to the lipidated vaccine against dengue virus infection. This does not alter the authors' adherence to all the PLoS Neglected Tropical Diseases policies on sharing data and materials. All other authors have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24069487</ArticleId><ArticleId IdType="pmc">PMC3777875</ArticleId><ArticleId IdType="doi">10.1371/journal.pntd.0002432</ArticleId><ArticleId IdType="pii">PNTD-D-13-00243</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chambers TJ, Hahn CS, Galler R, Rice CM (1990) Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 44: 649&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">2174669</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, et al. (2012) Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis 6: e1760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3413714</ArticleId><ArticleId IdType="pubmed">22880140</ArticleId></ArticleIdList></Reference><Reference><Citation>Coller BA, Clements DE (2011) Dengue vaccines: progress and challenges. Curr Opin Immunol 23: 391&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">21514129</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, et al. (2011) From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29: 7229&#x2013;7241.</Citation><ArticleIdList><ArticleId IdType="pubmed">21745521</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, et al. (2012) Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380: 1559&#x2013;1567.</Citation><ArticleIdList><ArticleId IdType="pubmed">22975340</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubler DJ, Clark GG (1995) Dengue/dengue hemorrhagic fever: the emergence of a global health problem. Emerg Infect Dis 1: 55&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2626838</ArticleId><ArticleId IdType="pubmed">8903160</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB (1988) Pathogenesis of dengue: challenges to molecular biology. Science 239: 476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">3277268</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60: 421&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">14689700</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KJ, Yang YC, Lin YS, Huang JH, Liu HS, et al. (2006) The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol 176: 2825&#x2013;2832.</Citation><ArticleIdList><ArticleId IdType="pubmed">16493039</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang YC, Lei HY, Lin YS, Liu HS, Wu HL, et al. (2011) Dengue virus-induced autoantibodies bind to plasminogen and enhance its activation. J Immunol 187: 6483&#x2013;6490.</Citation><ArticleIdList><ArticleId IdType="pubmed">22079981</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CF, Lei HY, Shiau AL, Liu HS, Yeh TM, et al. (2002) Endothelial cell apoptosis induced by antibodies against dengue virus nonstructural protein 1 via production of nitric oxide. J Immunol 169: 657&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">12097367</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu IJ, Chiu CY, Chen YC, Wu HC (2011) Molecular mimicry of human endothelial cell antigen by autoantibodies to nonstructural protein 1 of dengue virus. J Biol Chem 286: 9726&#x2013;9736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058979</ArticleId><ArticleId IdType="pubmed">21233208</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, et al. (1997) Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3: 866&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">9256277</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung J-J, Hsieh M-T, Young M-J, Kao C-L, King C-C, et al. (2004) An External Loop Region of Domain III of Dengue Virus Type 2 Envelope Protein Is Involved in Serotype-Specific Binding to Mosquito but Not Mammalian Cells. J Virol 78: 378&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC303388</ArticleId><ArticleId IdType="pubmed">14671119</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman MG, Hermida L, Bernardo L, Ramirez R, Guillen G (2010) Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines 9: 137&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">20109025</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardo L, Izquierdo A, Alvarez M, Rosario D, Prado I, et al. (2008) Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res 80: 194&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">18602424</ArticleId></ArticleIdList></Reference><Reference><Citation>Block OK, Rodrigo WW, Quinn M, Jin X, Rose RC, et al. (2010) A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice. Vaccine 28: 8085&#x2013;8094.</Citation><ArticleIdList><ArticleId IdType="pubmed">20959154</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang CY, Huang MH, Hsieh CH, Chen MY, Liu HH, et al. (2012) Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses. PLoS Negl Trop Dis 6: e1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3352863</ArticleId><ArticleId IdType="pubmed">22616020</ArticleId></ArticleIdList></Reference><Reference><Citation>Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, et al. (2010) Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 28: 2705&#x2013;2715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2837772</ArticleId><ArticleId IdType="pubmed">20097152</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng CH, Chen HW, Chang LS, Liu HH, Liu HY, et al. (2010) A recombinant lipoprotein containing an unsaturated fatty acid activates NF-kappaB through the TLR2 signaling pathway and induces a differential gene profile from a synthetic lipopeptide. Mol Immunol 47: 2015&#x2013;2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">20478617</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu T, Kida Y, Kuwano K (2008) A triacylated lipoprotein from Mycoplasma genitalium activates NF-kappaB through Toll-like receptor 1 (TLR1) and TLR2. Infect Immun 76: 3672&#x2013;3678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493199</ArticleId><ArticleId IdType="pubmed">18474641</ArticleId></ArticleIdList></Reference><Reference><Citation>Tawaratsumida K, Furuyashiki M, Katsumoto M, Fujimoto Y, Fukase K, et al. (2009) Characterization of N-terminal structure of TLR2-activating lipoprotein in Staphylococcus aureus. J Biol Chem 284: 9147&#x2013;9152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2666565</ArticleId><ArticleId IdType="pubmed">19218237</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakran S, Li H, Lavine CL, Miller MA, Bina JE, et al. (2008) Identification of Francisella tularensis lipoproteins that stimulate the toll-like receptor (TLR) 2/TLR1 heterodimer. J Biol Chem 283: 3751&#x2013;3760.</Citation><ArticleIdList><ArticleId IdType="pubmed">18079113</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HW, Liu SJ, Liu HH, Kwok Y, Lin CL, et al. (2009) A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine 27: 1400&#x2013;1409.</Citation><ArticleIdList><ArticleId IdType="pubmed">19150476</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng CH, Liu SJ, Tsai JP, Li YS, Chen MY, et al. (2009) A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect 11: 288&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">19114121</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Liao CL, Chen LK, Yeh CT, Liu CI, et al. (1998) Study of Dengue virus infection in SCID mice engrafted with human K562 cells. J Virol 72: 9729&#x2013;9737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110483</ArticleId><ArticleId IdType="pubmed">9811707</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WK, Lee CN, Kao CL, Lin YL, King CC (2000) Quantitative competitive reverse transcription-PCR for quantification of dengue virus RNA. J Clin Microbiol 38: 3306&#x2013;3310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC87378</ArticleId><ArticleId IdType="pubmed">10970375</ArticleId></ArticleIdList></Reference><Reference><Citation>Macdonald RA, Hosking CS, Jones CL (1988) The measurement of relative antibody affinity by ELISA using thiocyanate elution. J Immunol Methods 106: 191&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">3339255</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair N, Gans H, Lew-Yasukawa L, Long-Wagar AC, Arvin A, et al. (2007) Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis 196: 1339&#x2013;1345.</Citation><ArticleIdList><ArticleId IdType="pubmed">17922398</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok Y, Sung WC, Lin AL, Liu HH, Chou FA, et al. (2011) Rapid isolation and characterization of bacterial lipopeptides using liquid chromatography and mass spectrometry analysis. Proteomics 11: 2620&#x2013;2627.</Citation><ArticleIdList><ArticleId IdType="pubmed">21630453</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman MG, Vazquez S (2010) The complexity of antibody-dependent enhancement of dengue virus infection. Viruses 2: 2649&#x2013;2662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3185591</ArticleId><ArticleId IdType="pubmed">21994635</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Schaar HM, Wilschut JC, Smit JM (2009) Role of antibodies in controlling dengue virus infection. Immunobiology 214: 613&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">19261353</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson TC, Fremont DH, Kuhn RJ, Diamond MS (2008) Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4: 229&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678546</ArticleId><ArticleId IdType="pubmed">18779049</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, et al. (2007) The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1: 135&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656919</ArticleId><ArticleId IdType="pubmed">18005691</ArticleId></ArticleIdList></Reference><Reference><Citation>Mady BJ, Erbe DV, Kurane I, Fanger MW, Ennis FA (1991) Antibody-dependent enhancement of dengue virus infection mediated by bispecific antibodies against cell surface molecules other than Fc gamma receptors. J Immunol 147: 3139&#x2013;3144.</Citation><ArticleIdList><ArticleId IdType="pubmed">1680925</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CF, Lei HY, Shiau AL, Liu CC, Liu HS, et al. (2003) Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. J Med Virol 69: 82&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">12436482</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>